1. Home
  2. CTS vs MESO Comparison

CTS vs MESO Comparison

Compare CTS & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTS
  • MESO
  • Stock Information
  • Founded
  • CTS 1896
  • MESO 2004
  • Country
  • CTS United States
  • MESO Australia
  • Employees
  • CTS N/A
  • MESO N/A
  • Industry
  • CTS Electrical Products
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CTS Technology
  • MESO Health Care
  • Exchange
  • CTS Nasdaq
  • MESO Nasdaq
  • Market Cap
  • CTS 1.3B
  • MESO 1.4B
  • IPO Year
  • CTS N/A
  • MESO N/A
  • Fundamental
  • Price
  • CTS $40.46
  • MESO $10.34
  • Analyst Decision
  • CTS
  • MESO Buy
  • Analyst Count
  • CTS 0
  • MESO 4
  • Target Price
  • CTS N/A
  • MESO $18.00
  • AVG Volume (30 Days)
  • CTS 166.6K
  • MESO 226.8K
  • Earning Date
  • CTS 04-30-2025
  • MESO 02-26-2025
  • Dividend Yield
  • CTS 0.39%
  • MESO N/A
  • EPS Growth
  • CTS 16.02
  • MESO N/A
  • EPS
  • CTS 1.97
  • MESO N/A
  • Revenue
  • CTS $515,789,999.00
  • MESO $5,670,000.00
  • Revenue This Year
  • CTS $4.41
  • MESO $178.09
  • Revenue Next Year
  • CTS $7.00
  • MESO $305.06
  • P/E Ratio
  • CTS $20.64
  • MESO N/A
  • Revenue Growth
  • CTS N/A
  • MESO N/A
  • 52 Week Low
  • CTS $34.02
  • MESO $5.78
  • 52 Week High
  • CTS $59.68
  • MESO $22.00
  • Technical
  • Relative Strength Index (RSI)
  • CTS 48.64
  • MESO 38.84
  • Support Level
  • CTS $40.03
  • MESO $10.40
  • Resistance Level
  • CTS $40.93
  • MESO $11.26
  • Average True Range (ATR)
  • CTS 0.85
  • MESO 0.39
  • MACD
  • CTS -0.17
  • MESO -0.07
  • Stochastic Oscillator
  • CTS 26.56
  • MESO 2.50

About CTS CTS Corporation

CTS Corp operates in the electronics industry. The company is a manufacturer of Sensors, Electronic components, and Actuators. It designs, manufactures, and sells a broad line of sensors, electronic components, and actuators mainly to original equipment manufacturers (OEM) for the aerospace and defense, industrial, information technology, medical, telecommunications, and transportation markets. Geographically, it derives a majority of its revenue from the United States and also has a presence in China; Singapore; the Czech Republic; Taiwan, Denmark, and other countries.

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Share on Social Networks: